Vendor Intelligence Report: Changan District Sheng Peptide Trading

Published 3 Jul 2026. 23-page investigative report on who is behind Changan District Sheng Peptide Trading: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 8 Finnrick lab tests, Changan District Sheng Peptide Trading records 4 pass / 4 fail — an overall pass rate of 50%. The record is narrow: Retatrutide is the only Finnrick-tested product. It is visible, not persuasive, with an even split and a rating that loses margin under stricter grading. For a Retatrutide buyer, this is not a preferred-source signal; the rest of the catalog remains unproven under Finnrick data.

The infrastructure story is more concerning than the lab record alone. The Finnrick-listed peptide.press domain had expired and was available for registration in the July 2026 field run, while peptide-s.shop was live behind privacy protection and Cloudflare, hosted through shop910.net, and listing Jenny via WhatsApp. Because the successor domain existed before the old one dropped, the report treats it as a successor or parallel storefront rather than a clean relaunch.

Corporate and reputation checks sharpen the buyer-risk picture. Archived peptide.press assets point to Shenzhen Ayou Technology, but the storefronts did not publish a verifiable legal entity, official-channel list, address, licensing route, or audit-ready COAs. Public reputation evidence includes a buyer-reported GLP-1 Forum sequence involving Telegram, Bitcoin, no tracking, a Hong Kong customs-seizure explanation, and a 40% reship-fee demand; Nootroholic and Sakral Chimes keep the vendor on scam or avoid lists.

Inside the full report:

  • Appendix A Finnrick breakdown and methodology-divergence charts for the one tested product
  • WHOIS, Certificate Transparency, and Wayback evidence for peptide.press and peptide-s.shop
  • Archived storefront-claim checks against Shenzhen Ayou registry and supplier records
  • GLP-1 Forum Thread #7498 payment and shipping-failure sequence
  • Operator/contact map for Jenny He, Bella, Telegram ID 3175305409, and +852 WhatsApp
  • Supplier-network and US court-record exposure tied to Shenzhen Ayou

Risk assessment

  • Retatrutide quality-control risk — high: Retatrutide is the only Finnrick-tested product; 8 tests show 4 pass / 4 fail and a 68.66% rating.
  • Non-delivery and irreversible-payment risk — high: GLP-1 Forum and scam-list sources describe Telegram/WhatsApp operators, Bitcoin payment, no tracking, and a 40% reship-fee demand.
  • Shipping-origin and customs-loss risk — high: Community sources report US-warehouse claims while shipments allegedly originated from Hong Kong with customs-seizure narratives.
  • Corporate identity and licensing misrepresentation risk — high: Archived/current storefronts omit verifiable legal entity details while using FDA/ISO, production, Alibaba-customer and certificate claims not verified in records.
  • Brand-continuity and official-channel verification risk — high: peptide.press was expired/available in July 2026; peptide-s.shop is active under privacy/Cloudflare, and no authoritative domain, reseller, or COA-verification system was found.
  • Legal and enforcement-disruption risk — medium: Shenzhen Ayou, the entity indicated by archived assets, appears in two US Schedule A trademark cases; outcomes were not analyzed.